Halozyme Therapeutics (HALO) Shares Repurchased: 2019-2025
Historic Shares Repurchased for Halozyme Therapeutics (HALO) over the last 2 years, with Sep 2025 value amounting to $38.9 million.
- Halozyme Therapeutics' Shares Repurchased was N/A to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $691.3 million, marking a year-over-year change of. This contributed to the annual value of $250.0 million for FY2024, which is 37.87% down from last year.
- As of Q3 2025, Halozyme Therapeutics' Shares Repurchased stood at $38.9 million, which was down 84.45% from $250.0 million recorded in Q4 2024.
- Halozyme Therapeutics' 5-year Shares Repurchased high stood at $252.3 million for Q4 2023, and its period low was $1,000 during Q4 2022.
- In the last 3 years, Halozyme Therapeutics' Shares Repurchased had a median value of $200.0 million in 2023 and averaged $172.8 million.
- In the last 5 years, Halozyme Therapeutics' Shares Repurchased plummeted by 100.00% in 2022 and then soared by 25,229,900.00% in 2023.
- Over the past 5 years, Halozyme Therapeutics' Shares Repurchased (Quarterly) stood at $150.0 million in 2021, then plummeted by 100.00% to $1,000 in 2022, then skyrocketed by 25,229,900.00% to $252.3 million in 2023, then fell by 0.91% to $250.0 million in 2024, then reached $38.9 million in 2025.
- Its last three reported values are $38.9 million in Q3 2025, $250.0 million for Q4 2024, and $252.3 million during Q4 2023.